anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a medicine for preventing apoplexy, which belongs to a Chinese patent medicine made of Chinese herbal medicines as raw materials. The present invention also relates to a preparation method of the Chinese patent medicine. The medicine for preventing apoplexy mainly solves the technical problems of delay prevention and cure, high therapy cost, etc. existing in the existing medicine for treating apoplexy. The medicine of the present invention is composed of raw materials of the following proportion by weight: 12 to 18 g of unprocessed milkvetch root, 13 to 19 g of heterophylly falsestarwort root, 12 to 16 g of poria from Yunnan of China, 15 to 19 g of radix paeoniae alba from Hangzhou of China, 14 to 18 g of rehmannia root, 18 to 23 g of polygonatum, 12 to 17 g of light bamboo shavings, 8 to 12 g of unprocessed largehead atractylodes rhizome, 10 to 14 g of small liquorice, 7 to 12 g of radix angelicae sineinsis, 9 to 14 g of radix achyranthis bidentatae, 25 to 30 g of radix achyranthis bidentatae, 25 to 30 g of lalang grass rhizome, 10 to 15 g of chicken's gizzard-membrane, 28 to 35 g of hematite powder and 28 to 32 of saute mulberry twig. The method for preparing the medicine of the present invention has the following steps: the raw materials are weighed according to the proportion by weight at first; successively, the raw materials are ground into fine powder of 200 meshes; then, the raw materials are uniformly mixed and encapsulated.
Malignant melanoma (MM) is an aggressive tumor that can metastasize to any organ, but biliary tract metastasis is scarce. We describe a very rare case of MM metastasis to the common bile duct (CBD), presented with only dyspeptic symptoms. The patient had mildly elevated alkaline phosphatase and gamma-glutamyl transferase levels. Magnetic resonance cholangiopancreatography demonstrated a dilated common bile duct with a distal stricture. The MM diagnosis was established with the ampulla of Vater biopsy specimens obtained by endoscopic retrograde cholangiopancreatography (ERCP), and the patient's symptoms were resolved after biliary stenting. Both primary CBD cancer and other cancer types like MM that metastasize to CBD can cause obstruction and can be manifested only by dyspeptic symptoms. MM metastasis to CBD can cause obstruction manifested only by dyspeptic symptoms without obstructive jaundice. ERCP can be employed as a promising option for treatment and diagnosis. New-onset dyspeptic symptoms in patients with a history of MM should be investigated thoroughly, especially in the context of biliary metastasis.
A biocompatible biological component is provided comprising a membrane-mimetic surface film covering a substrate. Suitable substrates include hydrated substrates, e.g. hydrogels which may contain drugs for delivery to a patient through the membrane-mimetic film, or may be made up of cells, such as islet cells, for transplantation. The surface may present exposed bioactive molecules or moieties for binding to target molecules in vivo, for modulating host response when implanted into a patient (e.g. the surface may be antithrombogenic or antiinflammatory) and the surface may have pores of selected sizes to facilitate transport of substances therethrough. An optional hydrophilic cushion or spacer between the substrate and the membrane-mimetic surface allows transmembrane proteins to extend from the surface through the hydrophilic cushion, mimicking the structure of naturally-occurring cells. An alkylated layer directly beneath the membrane-mimetic surface facilates bonding of the surface to the remainder of the biological component. Alkyl chains may extend entirely through the hydrophilic cushion when present. To facilitate binding, the substrate may optionally be treated with a polyelectrolyte or alternating layers of oppositely-charged polyelectrolytes to facilitate charged binding of the membrane-mimetic film or alkylated layer beneath the membrane-mimetic film to the substrate. The membrane-mimetic film is preferably made by in situ polymerization of phospholipid vesicles.
Participants would be randomly assigned to either DoxyODPrEP or DoxyPEP arm, and be instructed to take doxycycline with the respective dosing schedule. They would be followed up for 24 months for nucleic acid amplification test (NAAT) and antibody tests against bacterial STI, namely chlamydia, gonorrhoea, and syphilis. The subjects and investigators would not be blinded due to its open-label nature, as the two arms' dosing schedules are different. Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex. Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex. At each clinic visit, urine, and pharyngeal and rectal swabs would be self-collected on-site by the participants following instructions. Pill count would be performed for each follow-up visit.
An improved antifungal composition for topical application to the skin and nails comprises: (1) an allylamine antifungal compound; (2) an aliphatic alcohol substituted with an aromatic substituent in which the allylamine antifungal compound is soluble to a degree that a therapeutically effective concentration of the allylamine antifungal compound can be applied topically in solution; (3) a lower aliphatic alcohol in which the aromatic alcohol is soluble; and (d) water or a water-compatible solvent mixture. The allylamine antifungal compound can be terbinafine or naftifine. The aliphatic alcohol substituted with an aromatic substituent can be benzyl alcohol or phenethyl alcohol. The lower aliphatic alcohol can be ethyl alcohol or isopropyl alcohol. In an alternative, the composition can further comprise an additional antifungal compound. Another aspect of the invention is a method for treatment of a fungal infection of skin or nails comprising administering the antifungal composition of the present invention topically to the skin or nails in an amount therapeutically effective to treat the fungal infection.
Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Reducing viral load is potentially key to reducing viral transmission between humans. Observational data suggests HC and AZ may reduce the viral load. In this study we will randomise ambulatory patients with Covid 19 (confirmed by PCR in combination with clinical symptoms) to receive HC/AZ or HC/placebo or placebo for 7 days. On days 2-14, participants will be reviewed by a member of the research team and samples will be obtained for viral load, an ECG recorded and physical examination performed. On days 15-20, participants will be reviewed by telephone using a semi structured questionnaire. On day 21 participants will be examined in person and an oronasopharyngeal swabs obtained for PCR analysis. Participants will be followed for 6 months via their medical records.
You should apply Refissa to your face once a day before retiring using only enough to cover the entire affected area lightly. Gently wash your face with a mild soap, pat the skin dry, and wait 20 to 30 minutes before applying Refissa. Apply a pea-sized amount of cream to cover your entire face. You may feel a warmth or slight stinging when Refissa is first applied.

You must be especially careful when applying the cream to avoid your eyes, ears, nostrils, or mouth. Refissa may cause severe redness, itching, burning, stinging, and peeling if applied to these areas.

Using larger than necessary amounts of Refissa will not speed results and can cause an overdose. An overdose can result in red and peeling skin as well as some pain or discomfort.

You may use cosmetics after applying Refissa. Make sure to clean your face thoroughly before applying Refissa again.
PURPOSE:A cosmetic having improved effect on hair breeding and hair growing action, dandruff and itch preventing action, beatifying action and skin activating action, prepared by blending an extracted component obtained by extracting the root of a variant of gramineous Sasanishiki (a kind of rice famous for its good taste) as an active ingredient with a cosmetic base. CONSTITUTION:A cosmetic prepared by blending an extracted component as an active ingredient obtained by extracting the root of a variant (Minisasanishiki) of gramineous Sasanishiki with a cosmetic base. The root of Minisasanishiki  dried in the shade is cut into a proper length of <=1cm, immersed in water, a  mixed solution of water and a hydrophilic solvent, a mixed solution of hydrophilic solvents, etc., and extracted preferably by cold immersion. The solvent is eliminated from the extracted crude essence by distillation or other method, so  the active ingredient is separated. The active amount of the Minisasanishiki extract based on the base is 0.001-10wt%, preferably 0.1-5wt%. The use of this  cosmetic together with the existing hair breeding, hair growing agent, and skin  beautifying agent provides synergistic actions.
Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
NEW MATERIAL:Peonone of formula. USE:An antiallergic agent having extremely low toxicity and an antiallergic activity of more than two times that of the monoterpene glucoside such as paeoniflorine, etc. It can be administered by oral administration, intravenous injection or subcutaneous injection. PROCESS:Peonone is prepared, e.g. by dissolving paeoniflorin extracted from root of Paeonia lactiflora or Paeonia moutan in methanol, and adding an alkali carbonate thereto. It is not necessary to separate and purify the paeoniflorin from the extract liquid containing the same, and the extract liquid can be added directly to a methanol solution of an alkali carbonate. The obtained solution containing peonone is concentrated in vacuum, dried, and subjected to silica gel column chromatography to obtain peonone.
The invention discloses a coix seed and lucid ganoderma liquor. Coix seeds, red dates, lucid ganoderma, rhizoma dioscoreae, herba cynomorii, radix polygoni multiflori, radix pseudostellariae and fructus rosae laevigatae are cleaned, stewed for 30 min and then put into a jar; then, grain liquor is added into the jar, the jar is sealed, brewing is carried out for 30 min at 115.5 DEG C, and the coix seed and lucid ganoderma liquor is obtained. On the basis of grain liquor, coix seeds, red dates, lucid ganoderma, rhizoma dioscoreae, herba cynomorii and other Chinese herbs are added, and thus the obtained coix seed and lucid ganoderma liquor has the effects of replenishing blood and maintaining beauty, and soothing the nerves, nourishing the kidneys and strengthening the essence. The invention further discloses a preparation process of the coix seed and lucid ganoderma liquor. As the raw materials are stewed and then brewed, functional ingredients in the medicinal materials can be better dissolved out; meanwhile, the sweetness of red dates is retained, it is unnecessary to add saccharide, and the product has a good taste and a better healthcare effect. The alcohol content of the obtained healthcare liquor is decreased, the healthcare liquor is easy to preserve and also suitable for people with a poor capacity for liquor, and thus the application range of the healthcare liquor is wider.
Antimicrobial nanocoatings may be a means of preventing nosocomial infections, which account for significant morbidity and mortality. The role of hospital sink traps in these infections is also increasingly appreciated. We describe the preparation, material characterization and antibacterial activity of a pipe cement-based silver nanocoating applied to unplasticized polyvinyl chloride, a material widely used in wastewater plumbing. Three-dimensional surface topography imaging and scanning electron microscopy showed increased roughness in all surface finishes versus control, with grinding producing the roughest surfaces. Silver stability within nanocoatings was >99.89% in deionized water and bacteriological media seeded with bacteria. The nanocoating exhibited potent antibiofilm (99.82-100% inhibition) and antiplanktonic (99.59-99.99% killing) activity against three representative bacterial species and a microbial community recovered from hospital sink traps. Hospital sink trap microbiota were characterized by sequencing the 16S rRNA gene, revealing the presence of opportunistic pathogens from genera including Pseudomonas, Enterobacter and Clostridioides. In a benchtop model sink trap system, nanocoating antibiofilm activity against this community remained significant after 11 days but waned following 25 days. Silver nanocoated disks in real-world sink traps in two university buildings had a limited antibiofilm effect, even though in vitro experiments using microbial communities recovered from the same traps demonstrated that the nanocoating was effective, reducing biofilm formation by >99.6% and killing >98% of planktonic bacteria. We propose that conditioning films forming in the complex conditions of real-world sink traps negatively impact nanocoating performance, which may have wider relevance to development of antimicrobial nanocoatings that are not tested in the real-world.
Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
The increasing prevalence of type 2 diabetes mellitus (T2DM) is a significant worldwide health concern caused by sedentary lifestyles and unhealthy diets. Beyond glycemic control, T2DM impacts multiple organ systems, leading to various complications. While traditionally associated with cardiovascular and microvascular complications, emerging evidence indicates significant effects on pulmonary health. Pulmonary vascular dysfunction and fibrosis, characterized by alterations in vascular tone and excessive extracellular matrix deposition, are increasingly recognized in individuals with T2DM. The onset of T2DM is often preceded by prediabetes, an intermediate hyperglycemic state that is associated with increased diabetes and cardiovascular disease risk. This review explores the relationship between T2DM, pulmonary vascular dysfunction and pulmonary fibrosis, with a focus on potential links with prediabetes. Pulmonary vascular function, including the roles of nitric oxide (NO), prostacyclin (PGI2), endothelin-1 (ET-1), thromboxane A2 (TxA2) and thrombospondin-1 (THBS1), is discussed in the context of T2DM and prediabetes. Mechanisms linking T2DM to pulmonary fibrosis, such as oxidative stress, dysregulated fibrotic signaling, and chronic inflammation, are explained. The impact of prediabetes on pulmonary health, including endothelial dysfunction, oxidative stress, and dysregulated vasoactive mediators, is highlighted. Early detection and intervention during the prediabetic stage may reduce respiratory complications associated with T2DM, emphasizing the importance of management strategies targeting blood glucose regulation and vascular health. More research that looks into the mechanisms underlying pulmonary complications in T2DM and prediabetes is needed.
Thefollowing adverse events have been identified during postapproval use oflevetiracetam. Because these events are reported voluntarily from a populationof uncertain size, it is not always possible to reliably estimate theirfrequency or establish a casual relationship to drug exposure.

In addition to the adverse experiences listed above,the following have been reported in patients receiving marketed levetiracetam worldwide. The listing is alphabetized:abnormal liver function test, hepatic failure, hepatitis, leukopenia,neutropenia, pancreatitis, pancytopenia (with bone marrow suppressionidentified in some of these cases), thrombocytopenia, and weight loss. Alopeciahas been reported with levetiracetam use; recoverywas observed in majority of cases where levetiracetamwas discontinued. These adverse experiences have not been listed above, anddata are insufficient to support an estimate of their incidence or to establishcausation.
The "Agricultural Health Study" (AHS) is a collaborative effort between the National Cancer Institute and the National Institute of Environmental Health Sciences. The U.S. Environmental Protection Agency and the National Institute for Occupational Safety and Health are providing support for a limited exposure assessment effort. Initial data collection on a prospective cohort of 89,655 study subjects has been completed as of December 1997. Participants completed questionnaires that included items on pesticides used, other agricultural exposures, and work practices that modify exposure as well as on other activities that may affect either exposure or disease risks (e.g., diet, exercise, alcohol consumption, medical conditions, family history of cancer, other occupations and smoking history). Phase II of the study (1998-2003) updated information on occupational exposures, diet, work practices and medical history by means of a computer assisted telephone interview. We also collected buccal cells on sample of 34,000 study participants to assess the effect of inheritable polymorphisms and the interaction of environment and genomic predisposition. The stimulus for this prospective investigation comes from the growing evidence that, despite a low mortality overall, farmers experience an excess of several cancers. These excesses have been observed in retrospective epidemiological studies among agricultural workers in several countries. Excess cancers are observed for the lymphatic and hematopoietic system, connective tissue, skin, brain, prostate, stomach and lips. Several of these tumors (brain, NHL, multiple myeloma, and prostate) are also increasing in the general population in many of these countries. This suggests a common set of exposures may explain the high rates in farmers and rising rates in the general population.

Farmers, their families, and other pest control workers may have contact with a variety of potentially hazardous substances including pesticides, solvents, fuels and oils, engine exhaust, dust and zoonotic viruses and other microbes. Our cohort study includes all registered pesticide applicators in Iowa and North Carolina and the spouse of applicators who are farmers. The health effects of pesticide use are the primary focus of the study. The influence of other farm exposures are also being evaluated.
Apply a thin film of Betamethasone Valerate Cream or Ointment to the affected skin areas one to three times a day. Dosage once or twice a day is often effective.

Apply a few drops of Betamethasone Valerate Lotion to the affected area and massage lightly until it disappears. Apply twice daily, in the morning and at night. Dosage may be increased in stubborn cases. Following improvement, apply once daily. For the most effective and economical use, apply nozzle very close to affected area and gently squeeze bottle.
The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
Vitamin B12 is an essential nutrient for normal DNA-synthesis and must be supplied by animal products. Vitamin B12 deficiency may cause anemia and irreverible neurological damage. Laboratory tests are used for diagnosis of vitamin B12 deficiency, and following the diagnosis, the cause of the vitamin B12 deficiency has to be clarified. For years a test called Shilling's test has been used for evaluation of the vitamin B12 absorption. However, the Schilling's test is no longer easy accessible because of increasing difficulties to obtain the radioactively labeled vitamin B12 requested, and native human intrinsic factor for Schilling's test II (absorption of vitamin B12 attached to intrinsic factor) is no longer available in most countries. Recently, human intrinsic factor unsaturated with vitamin B12 has been expressed in the plant Arabidopsis thaliana. The purpose of this study was to examine whether recombinant human intrinsic factor is able to promote the uptake of vitamin B12 in patients with evident vitamin B12 deficiency.
Removal of the SUSVIMO ocular implant is a surgical procedure that is performed in an operating room. The procedure must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery [see Dosage and Administration (2.1)].

After placing an infusion line in the eye, create at least a 6×6 mm peritomy of the conjunctiva and Tenon's capsule around the SUSVIMO ocular implant flange. Remove any fibrous capsule or scar tissue that may have formed over the implant flange and septum using scalpel and forceps. With the explant tool oriented perpendicular to the globe, align the contoured tips with the long axis of the implant flange and grasp underneath the implant flange. Once the implant is secured in the explant tool, pull the implant from the eye in a perpendicular motion. Clear any vitreous prolapse present within or around the scleral wound using a vitrector. Completely close the scleral incision with multiple non-absorbable sutures. Close the Tenon's capsule and conjunctiva to completely cover the scleral incision. Refer to the complete Instructions for Use for the implant removal procedure included in the explant tool carton for further details.